- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00446797
Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
GO
-
Goiânia, GO, Brazil, 74075-020
- Pfizer Investigational Site
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 20221-161
- Pfizer Investigational Site
-
-
SP
-
São Paulo, SP, Brazil, 01221-900
- Pfizer Investigational Site
-
São Paulo, SP, Brazil, 02720-000
- Pfizer Investigational Site
-
-
-
-
Guadalupe, San Jose
-
San Antonio Guadalupe, Guadalupe, San Jose, Costa Rica
- Pfizer Investigational Site
-
-
-
-
Pichincha
-
Quito, Pichincha, Ecuador
- Pfizer Investigational Site
-
-
-
-
-
Cairo, Egypt
- Pfizer Investigational Site
-
-
-
-
-
Amman, Jordan, 11181 Jordan
- Pfizer Investigational Site
-
Amman, Jordan, 11193 Jordan
- Pfizer Investigational Site
-
Amman, Jordan, 22110 Jordan
- Pfizer Investigational Site
-
-
-
-
-
México DF, Mexico, 03020
- Pfizer Investigational Site
-
-
DF
-
Mexico, DF, Mexico, 10700
- Pfizer Investigational Site
-
-
Estado De México
-
Toluca, Estado De México, Mexico, 50180
- Pfizer Investigational Site
-
-
Nuevo León
-
San Nicolas de los Garza, Nuevo León, Mexico, 66451
- Pfizer Investigational Site
-
-
-
-
-
Panama City, Panama
- Pfizer Investigational Site
-
-
-
-
-
Lima, Peru, L27
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with first acute ankle sprain episode in the last six months classified as grade I or II, confirmed by X-rays, according to the following definitions:
- Grade I: When the ligament is stretched but not torn and the anterior talofibular ligament is usually involved. The anterior draw test is negative.
- Grade II: Moderate sprains which usually result in partial tears af the ligaments, primarily the anterior talofibular and possibly the calcaneofibular ligament. Ligamentous laxity may be present and there is moderate swelling.
Exclusion Criteria:
- Patients who have a similar injury of the same joint within the last six months; or
- clinical evidence of complete rupture of ankle ligaments (third degree sprain), or
- requirements for bed rest, hospitalization, surgical intervention for the ankle injury; or
- evidence of fractures; or non-removable full cast of any tipe; or
- presence of bilateral occurrence of ankle injury or ipsilateral ankle and knee injury.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Celecoxib
|
celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
|
Active Comparator: Non-Selective NSAIDS
nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
|
Non-selective NSAIDs administered at usual (standard) doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population
Time Frame: Baseline and day 3
|
Assessment of ankle pain by VAS: 100 mm horizontal line with left end being "No Pain" & right end being "Worst Possible Pain".
Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle.
Distance from left end of line to mark.
Change: mean score at day 3 minus mean score at baseline
|
Baseline and day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population
Time Frame: Baseline and days 2, 3 and 7
|
Assessment of ankle pain by VAS: 100 mm horizontal line, left end being "No Pain" & right end being "Worst Possible Pain".
Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle.
Distance from left end of line to mark.
Change: mean score at observation minus mean score at baseline
|
Baseline and days 2, 3 and 7
|
Number of Subjects Responding (Improving) - MITT Population
Time Frame: Days 2, 3 and 7
|
The number of subjects showing a response: a decrease of at least 20 mm (that is improvement) on the pain visual analog scale (VAS) scale
|
Days 2, 3 and 7
|
Subject's Global Assessment of Ankle Injury
Time Frame: Days 2, 3 and 7
|
Subject response to question: "Considering all the ways your ankle injury affects you, how are you doing today?"
Scale: 5 point from 1 = very good (no symptoms and no limitation of normal activities) to 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities).
|
Days 2, 3 and 7
|
Physician Global Assessment of Ankle Injury
Time Frame: Days 3 and 7
|
Investigator evaluation of overall severity of ankle injury.
Scale: 5 point from 1 = Very mild (very mild signs and symptoms of ankle sprain) to 5 =Very severe (very severe signs and symptoms of ankle sprain)
|
Days 3 and 7
|
Pain Relief - MITT Population
Time Frame: Days 2, 3 and 7
|
Subject's response to the statement "My relief from starting pain is".
Scale from 0 = None to 4 = Complete.
|
Days 2, 3 and 7
|
Subject Assessment of Normal Function / Activity
Time Frame: Days 2, 3 and 7
|
Subject response to question: "How does your ankle injury affect your walking and normal activity?"
Scale from 1 = Normal walking/activity and no pain to 5 = Severely restricted walking due to pain and can't resume normal activities (normal activities defined as all activity that a subject did on a routine basis, including work and recreation)
|
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1
Time Frame: Days 1, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q1: Subject response to 'describe your pain at its worst in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine |
Days 1, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q2: Subject response to 'describe your pain at its least in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q3: Subject response to 'describe your pain on the average'. Scale: 0 = no pain to 10 = pain as bad as you can imagine |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q4: Subject response to 'how much pain you have right now'. Scale: 0 = no pain to 10 = pain as bad as you can imagine |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Pain severity index is the average of the pain severity questions 1 to 4. Scale: 0 = no pain to 10 = pain as bad as you can imagine |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5A
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5B
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5C
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5D
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5E
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5F
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5G
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Index
Time Frame: Days 2, 3 and 7
|
m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period. The pain interference index is the average of pain interference questions 5A to 5G. Scale: 0 = does not interfere to 10 = completely interferes |
Days 2, 3 and 7
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Wounds and Injuries
- Leg Injuries
- Acute Pain
- Sprains and Strains
- Ankle Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Celecoxib
Other Study ID Numbers
- A3191332
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankle Sprain
-
Decathlon SEEFOR, FranceTerminatedAnkle Sprain 1St Degree | Ankle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeFrance
-
National Defense Medical Center, TaiwanTri-Service General HospitalRecruitingAnkle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeTaiwan
-
Instituto Mexicano del Seguro SocialCompletedAnkle Sprain | Ankle Sprain 1St Degree | Ankle Sprain 2Nd DegreeMexico
-
Université Catholique de LouvainCompletedAnkle Sprain 1St Degree | Ankle Sprain 2Nd DegreeBelgium
-
Vanderbilt University Medical CenterRecruitingMusculoskeletal Injury | Ankle Sprain 1St Degree | Ankle Sprain 2Nd DegreeUnited States
-
University of VirginiaNational Athletic Training Association Research & Education FoundationUnknownLateral Ankle SprainUnited States
-
Hospital Universitario Infanta LeonorCompletedMild Ankle SprainSpain
-
University Hospital, GrenobleCompleted
-
Université Catholique de LouvainUZ Leuven, campus Pellenberg (Belgium)RecruitingChronic Ankle Instability | Lateral Ankle SprainBelgium
Clinical Trials on Non-selective NSAIDS
-
The First Affiliated Hospital of Xiamen UniversityFirst Affiliated Hospital of Fujian Medical University; Fujian Medical University... and other collaboratorsRecruitingAxial SpondyloarthritisChina
-
Jordan University of Science and TechnologyRecruiting
-
Vastra Gotaland RegionGöteborg UniversityRecruitingThyroid Cancer | Thyroid NoduleSweden
-
Hoffmann-La RocheCompletedJuvenile Idiopathic ArthritisChina
-
Universidad Católica de ÁvilaActive, not recruitingHumeral Epicondylitis, LateralSpain
-
Taksim Egitim ve Arastirma HastanesiCompleted
-
Organon and CoCompleted
-
Jagiellonian UniversityCompleted
-
University Hospital, BordeauxActive, not recruiting
-
University of CopenhagenGöteborg University; University of Aarhus; National Health Insurance foundation; Dan Dental A... and other collaboratorsCompletedDental Caries | Reversible PulpitisDenmark